Get started
Author

Nabila Nora Bennani

Observed names: N. N. Benani, Nabila Bennani, Nabila N. Bennani, Nabila Nora Benani
Institution: Mayo Clinic
OpenAlex ID: A5104035259
Sustained, complete response to pexidartinib in a patient with CSF1R ‐mutated Erdheim–Chester disease
2022 · Jithma P. Abeykoon, Terra L. Lasho, et al. · American Journal of Hematology · 26
Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients.
2019 · Gaurav Goyal, Marie Hu, et al. · Journal of Clinical Oncology · 15
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.
2023 · Radhika Bansal, Jonas Paludo, et al. · Journal of Clinical Oncology · 12
PDF
Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.
2021 · Radhika Bansal, Jonas Paludo, et al. · Journal of Clinical Oncology · 11
The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis
2017 · Martin Bjerregård Pedersen, Thomas Relander, et al. · Blood · 11
Peak absolute lymphocyte count after CAR‐T infusion predicts clinical response in aggressive lymphoma
2022 · Radhika Bansal, Mattia Novo, et al. · American Journal of Hematology · 7
PDF
Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).
2019 · Surbhi Sidana, Amylou C. Dueck, et al. · Journal of Clinical Oncology · 7
ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma
2019 · Ran Reshef, David B. Miklos, et al. · Blood · 6
Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)
2018 · Thomas M. Habermann, Angelo Fama, et al. · Blood · 5
Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era
2017 · Gita Thanarajasingam, Matthew J. Maurer, et al. · British Journal of Haematology · 5
QIM19-136: Developing an Ideal CAR-T Cell Therapy Patient Experience Through Human-Centered Design and Innovation
2019 · Allison Matthews, Surbhi Sidana, et al. · Journal of the National Comprehensive Cancer Network · 4
In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).
2022 · Omran Saifi, William Breen, et al. · Journal of Clinical Oncology · 3
PJP pneumonia in brentuximab vedotin recipients.
2022 · Caleb Scheckel, Jithma P. Abeykoon, et al. · Journal of Clinical Oncology · 3
Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL)
2020 · Arushi Khurana, Matthew A Hathcock, et al. · Blood · 3
Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.
2023 · Nabila Nora Bennani, Joselle Cook, et al. · Journal of Clinical Oncology · 2
Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.
2023 · Kah Whye Peng, Adam Remick, et al. · Journal of Clinical Oncology · 2
Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
2020 · Arushi Khurana, Abdullah S. Al Saleh, et al. · Blood · 2
Clinical utility of molecular testing to select therapy in relapsed/refractory non-Hodgkin lymphoma: Mayo Clinic Center for Individualized Medicine experience.
2017 · Nabila Nora Bennani, Stephen Maxted Ansell, et al. · Journal of Clinical Oncology · 2
Diffuse Large B Cell Lymphoma: Role Of MYC, BCL2, BCL6 Protein Expressions and Translocations
2013 · Susmita Sakruti, Nabila Bennani, et al. · Blood · 2
Machine learning-based prediction of cytokine release syndrome post CAR-T cell therapy.
2025 · Jonas Paludo, Jacob T Shreve, et al. · Journal of Clinical Oncology · 1
PDF
Clinical characteristics and treatment outcomes of hepatosplenic T-cell lymphoma: Mayo Clinic experience.
2025 · Syeda A. Mina, Raphael Mwangi, et al. · Journal of Clinical Oncology · 1
Metformin and cytokine release syndrome after immune effector cell therapy.
2024 · Aytaj Mammadzadeh, Radhika Bansal, et al. · Journal of Clinical Oncology · 1
Insurance status and survival in diffuse large B-cell lymphoma: A National Cancer Database study before and after the Affordable Care Act.
2021 · Antoine N Saliba, Xavier Andrade-Gonzalez, et al. · Journal of Clinical Oncology · 1
Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia
2020 · Paul J. Hampel, Sameer A. Parikh, et al. · Blood · 1
Onset, duration, and clinical impact of immune-related adverse events in Hodgkin lymphoma.
2020 · Alexandra Higgins, Michael D. Richter, et al. · Journal of Clinical Oncology · 1
Works count: 41
Citation count: 136
H-index: 7
I10-index: 5
Year
Topic
Type